RMC No. 27-2026 updates the FDA-endorsed VAT-exempt drug list for cancer, diabetes, hypertension, kidney disease, mental illness, and more.

Businesses selling covered medicines must immediately check whether their pharmacy, hospital, distribution, accounting, and point-of-sale systems reflect the updated VAT-exempt drug list endorsed by the Food and Drug Administration. RMC No. 27-2026 publishes the updated full list of VAT-exempt drugs for certain illnesses under the TRAIN Law and the CREATE Act, and it expressly supersedes previous Revenue Memorandum Circulars on the same subject until the FDA endorses new updates.

What RMC No. 27-2026 changes

RMC No. 27-2026 publishes the full text of the February 6, 2026 letter from the Food and Drug Administration of the Department of Health, through Director General Dr. Paolo S. Teston, endorsing the updated full list of VAT-exempt drugs under Republic Act No. 10963, also known as the TRAIN Law, and Republic Act No. 11534, also known as the CREATE Act.

The practical change is that taxpayers must use the updated FDA-endorsed list as the controlling reference for drugs treated as VAT-exempt for the covered illnesses. The circular is not merely a general announcement. It confirms that the updated list applies to the VAT-exempt drugs for the enumerated illnesses and that prior Revenue Memorandum Circulars on the matter are superseded, until new updates are endorsed by the FDA.

For businesses, this matters because medicine VAT treatment is highly transactional. A covered drug may be sold through pharmacies, hospital billing systems, clinics, wholesalers, distributors, and other medicine supply chains. If the seller continues using an older internal list, the business may charge VAT on a drug that should be treated as VAT-exempt, or may fail to properly classify products in its accounting system. Either mistake can trigger customer complaints, reconciliation issues, and tax compliance exposure.

Updated VAT-exempt drug categories and figures

RMC No. 27-2026 summarizes the number of exempt drugs by illness. The updated list covers 702 drugs for cancer, 327 drugs for diabetes, 171 drugs for high cholesterol, 535 drugs for hypertension, 152 drugs for kidney disease, 300 drugs for mental illness, and 76 drugs for tuberculosis.

The largest category in the summary is cancer, with 702 VAT-exempt drugs. Hypertension follows with 535 VAT-exempt drugs, then diabetes with 327, mental illness with 300, high cholesterol with 171, kidney disease with 152, and tuberculosis with 76. These figures are important for pharmacies, hospitals, and medicine retailers because they indicate the scope of products that may require system tagging, product master file review, and branch-level implementation.

Accountants and tax managers searching for BIR VAT-exempt medicines 2026, FDA VAT-exempt drug list, VAT exemption cancer medicines Philippines, VAT-exempt drugs diabetes hypertension, or RMC 27-2026 VAT-exempt medicines should treat the issuance as a compliance update requiring actual operational changes, not merely a tax advisory to be filed for reference.

Who is most affected

The taxpayers most directly affected are businesses that sell, distribute, dispense, or bill medicines for the covered illnesses. This includes VAT-registered pharmacies, hospital pharmacies, hospitals and clinics with medicine billing, drug wholesalers, drug distributors, medicine importers, health maintenance and medical service groups that process drug-related charges, and corporate accounting teams responsible for tax classification of inventory.

The issuance also matters to corporate purchasers and institutional buyers because the VAT status of a covered drug affects purchase costing, invoice review, reimbursement processing, and internal audit. A company that operates clinics for employees or purchases medicines in volume should ensure that its procurement and accounting teams are aligned with the updated FDA-endorsed list.

For internal revenue officials and BIR personnel, the circular provides guidance on which FDA-endorsed list should be recognized. For private businesses, the immediate task is to align product-level treatment with the updated list so that sales documents, accounting entries, customer receipts, and VAT reports are consistent.

Effective date and compliance deadline

RMC No. 27-2026 is dated April 8, 2026. The circular does not state a separate future effectivity date or a transition period. It directs all concerned to be guided accordingly and to give the circular as wide a publicity as possible. In practical compliance terms, affected businesses should treat the April 8, 2026 issuance date as the date from which their teams should move to validate and implement the updated list.

The more urgent point is that previous Revenue Memorandum Circulars on VAT-exempt drugs for the same covered illnesses are superseded until new updates are endorsed by the FDA. This means that a taxpayer should not rely on an older BIR circular if the product classification is now covered by the updated FDA-endorsed list published through RMC No. 27-2026.

Penalties and risks for non-compliance

RMC No. 27-2026 does not prescribe a special penalty provision. However, the absence of a special penalty in the circular should not be read as permission to delay implementation. The key compliance risk is incorrect VAT treatment of medicines that fall within the updated FDA-endorsed list, especially where a business continues to use an outdated product database or branch-level price file.

The operational risks include charging customers incorrectly, issuing invoices or receipts with inconsistent VAT treatment, creating mismatches between inventory records and tax reports, and requiring later corrections across multiple branches or systems. For large pharmacy chains, hospitals, and distributors, the practical exposure may be multiplied because the same master file error can affect many transactions.

Practical steps for pharmacies, hospitals, and distributors

First, tax and accounting teams should obtain the updated FDA-endorsed VAT-exempt drug list referenced in RMC No. 27-2026 and compare it against the company product master file. The review should be done at the SKU or product-code level, not merely by illness category, because VAT treatment must be correctly applied at the point of sale or billing.

Second, businesses should update point-of-sale systems, hospital billing platforms, ERP systems, inventory databases, and e-invoicing or receipt templates where applicable. The goal is to ensure that covered drugs are tagged consistently from purchase to inventory to sale.

Third, branch personnel and billing teams should be informed that prior internal lists based on earlier circulars may no longer be reliable. The circular expressly states that previous Revenue Memorandum Circulars are superseded until new FDA-endorsed updates are issued.

Fourth, companies should retain documentation showing when the updated list was reviewed, who approved the tax classification changes, and when the system updates were implemented. This is especially important for businesses with multiple branches or decentralized billing operations.

How Ablola, Saribong & Gueco can help

RMC No. 27-2026 is a product-level VAT compliance update that can affect pricing, billing, invoicing, tax reporting, and customer-facing transactions. Ablola, Saribong & Gueco assists pharmacies, hospitals, distributors, healthcare businesses, and corporate taxpayers in reviewing BIR issuances, aligning internal tax classifications, and preparing practical compliance steps for implementation across business units.

For assistance with VAT-exempt drug compliance, BIR audit readiness, tax classification review, or healthcare-related tax issues in the Philippines, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *